Promega UK Announces Lumit^®
Grant Recipients

Promega UK (4 June 2024) is delighted to announce the recipients of the 2024 Lumit^® Grant, whereby four researchers have received funding to convert their current immunoassays to Lumit^® Immunoassays. 22 high-quality applications were received from leading academic institutions across the UK, demonstrating strong interest in Promega’s innovative Lumit^® Technology.

The Lumit^® Grant provides recipients with Lumit^® kits or reagents, funding for third-party reagents such as primary antibodies, and dedicated technical support. Lumit^® Immunoassays are based on NanoBiT^® split-luciferase technology and enable sensitive luminescence-based detection of specific antigens or antibodies, simplifying immunoassay protocols and speeding up time to results. Lumit^® powers sensitive and accurate immunoassays for research, QC and clinical applications.

Dr Hilary Pollard says, “We are delighted to support four researchers in converting their current immunoassays to a Lumit^® immunoassay workflow. We received a large number of applications against a broad range of target proteins. After a careful selection process, we’re looking forward to working with the scientists and seeing the increases in efficiency that Lumit^® offers them.”

The selection process was rigorous, with applications initially screened by Dr Hilary Pollard, Senior Product Manager; Dr Craig Malcolm, Business Manager – Emerging Technologies and  Dr Lucy Wheatley, Project Manager - Emerging Technologies. The shortlist of eight applications received additional review by the US Lumit^® Product Management Team and Dr Mark Coldwell, UK Technical Support Scientist. The four winners were chosen based on the merit and feasibility of their proposals and were notified of their success at the end of their interviews.

The winners selected are from King’s College London, University College London, University of Exeter and University of Strathclyde.

Promega UK is looking forward to working closely with the grant recipients over the coming months to ensure successful implementation of Lumit^® Technology in their research.

What is Lumit ^® Technology?

Lumit^® Immunoassays are a disruptive technology for performing immunoassays, which are laboratory tests used to detect specific proteins orother substances in a sample. Traditional immunoassays can be time-consuming and may require complex handling steps which can introduce errors. Lumit^® Technology simplifies the immunoassay process by using a luminescence-based detection method, which means it uses light to detect the presence of specific targets.

Here’s why Lumit^® is a better solution for scientists:

• Simplified Process: Lumit^® Immunoassays are streamlined with fewer steps and less hand-on time compared to traditional immunoassays.
• Speed: The simple protocol and use of light as an output means that results can be obtained much faster than traditional methods.
• Sensitivity and Accuracy: Lumit^® Technology is highly sensitive and accurate, making it possible to detect even very small amounts of the target substance.
• Versatility: Lumit^® can be used for a wide range of applications, including research, quality control (QC) and clinical diagnostics.
• Throughput: Lumit^® Immunoassays are scalable, allowing for their use with automation in high throughput laboratories.

Why It Matters

Accurate results are crucial for scientists. By using Lumit^® Immunoassays, researchers can get more accurate results in a shorter timeframe, allowing them to focus on data analysis, rather than sample processing. This results in a greater volume of data and faster progress, ultimately leading to more scientific breakthroughs.

________________________________________________

Media Contact:
Phil Hargreaves
Director, Strategic Marketing & Business Development
Promega UK

E: philip.hargreaves@promega.com
T: 07801 348327

Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s 4,000 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, drug discovery and human identification. Founded in 1978, the company is headquartered in Madison, WI, USA with branches in 16 countries and over 50 global distributors. For more information about Promega, visit www.promega.com.